ClinicalTrials.gg
RecruitingNCT06970353Updated Aug 7, 2025

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

A Phase 2 interventional study of Tunlametinib and Tunlametinib+PD-1 mAb in Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation and Advanced PDTC or ATC With NRAS Mutation, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Thyroid Neoplasms by Fudan University — 11 open to participants now, 11 under way, 2 of them phase 3. Thyroid Neoplasms · Fudan University.

Planned enrollment
9th of 14
40 · median 66
Started
2025
with 1 other
Phase 2
9 of 17
5 open now
Primary completion
2026-12
later than 1 of 10 live
Registered
13th of 17
by date

Among the 17 studies in Thyroid Neoplasms by Fudan University, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 13th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

11 of the 17 studies in Thyroid Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Thyroid Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This phase II trial evaluates Tunlametinib (MEK inhibitor) ± PD-1 in NRAS-mutant advanced thyroid cancer.

Key Objectives:

Assess efficacy (ORR by RECIST v1.1) Evaluate safety profiles

Study Design:

Single-arm, single-center 4 cohorts based on:

  • Histology (differentiated vs. poorly/undifferentiated)
  • Prior therapy status

Treatment:

  • Cohorts 1-2: Tunlametinib monotherapy (12mg BID)
  • Cohorts 3-4: Tunlametinib + PD-1 (commercially available)

Key Procedures:

Screening: NRAS testing + full staging (CT/MRI/PET) Monitoring: q3-week labs, q9-week imaging Follow-up: 30-day safety visit + q3-month survival tracking

Endpoints:

Primary: ORR Secondary: Safety (CTCAE), PFS, DoR

Unique Aspects:

First study targeting NRAS in thyroid cancer with MEK+PD-1 Includes rare aggressive subtypes (poorly/undifferentiated)

Read the detailed description

Research Objective:

To evaluate the efficacy and safety of Tunlametinib (monotherapy or in combination with PD-1 mAb) in patients with locally advanced or metastatic NRAS-mutant thyroid cancer.

Study Endpoints:

Primary Endpoint:

Objective response rate (ORR) assessed per RECIST v1.1 (sum of partial and complete response rates).

Secondary Endpoints:

Efficacy:

Disease control rate (DCR) Duration of response (DoR) Time to response (TTR) Progression-free survival (PFS) Overall survival (OS), 6-month survival rate, 12-month survival rate

Safety:

Adverse events (AEs): Type, incidence, severity (graded by NCI-CTCAE v5.0), duration, and relationship to study treatment

Study Design:

This is a prospective, single-arm, open-label, single-center Phase II exploratory trial evaluating Tunlametinib ± PD-1 mAb in NRAS-mutant thyroid cancer.

Study Phases:

Screening: ≤28 days prior to enrollment (informed consent to baseline assessments).

Treatment: Until disease progression, intolerable toxicity, consent withdrawal, or investigator decision.

Follow-up:

Safety visit at 30 days (±7) post-treatment. Survival follow-up every 3 months (telephone/medical records).

Cohorts \& Treatment:

Cohort 1 (n=10): Untreated, radioactive iodine-refractory, differentiated thyroid cancer.

Cohort 2 (n=10): Previously treated, radioactive iodine-refractory, differentiated thyroid cancer.

Regimen: Tunlametinib 12 mg BID (3-week cycles).

Cohort 3 (n=10): Untreated, poorly differentiated/anaplastic thyroid cancer.

Cohort 4 (n=10): Previously treated, poorly differentiated/anaplastic thyroid cancer.

Regimen: Tunlametinib 12 mg BID + PD-1 mAb(commercially available; per approved labeling).

Dose Adjustments:

Tunlametinib: Stepwise reduction (12 mg → 9 mg → 6 mg BID) for intolerance. Re-escalation permitted if toxicity resolves (e.g., 6 mg → 9 mg after ≥6 weeks).

PD-1: Adjusted per investigator judgment and drug labeling.

Efficacy Assessments:

Imaging (CT/MRI) every 9 weeks (3 cycles) per RECIST v1.1. Real-time ORR analysis by investigators and sponsor (Shanghai Kezhou Pharmaceutical).

Follow-up Procedures:

Safety visit: Day 30 (±7) post-treatment (vitals, labs, AE assessment). Survival follow-up: Quarterly until death/loss to follow-up/study termination.

03

Conditions studied

  • Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation
  • Advanced PDTC or ATC With NRAS Mutation

Browse trials for

Keywords

  • NRAS mutant
  • Locally advanced thyroid cancer
  • Thyroid cancer
  • Metastatic thyroid cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients voluntarily join this study and sign an form;
  2. Age: ≥ 18 years old, male or female not limited;
  3. For locally advanced or recurrent/ thyroid cancer diagnosed by histology and unable to undergo curative surgery, one of the following requirements must be met:

    1. Iodine thyroid cancer;
    2. Differentiated thyroid cancer not suitable for iodine therapy;
    3. High grade, poorly differentiated or poorly differentiated thyroid cancer;
    4. Undifferentiated thyroid carcinoma;
  4. Have undergone NGS testing (at our hospital or an external hospital), and be able to find that the test report or medical history has recorded a positive result for NRAS mutation in the gene test.
  5. score 0-2 points; According to v1.1 evaluation, there is at least one assessable lesion;

7. Expected survival>12 weeks; 8. The main organ function and bone marrow function are normal.

  • Blood routine: ≥ 90 g/L (no blood transfusion within 14 days); ≥ 1.5 × 109/L; count ≥ 100 × 109/L;
  • Liver function: (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) are ≤ 2.5 times the (ULN). If there is liver metastasis, ALT and AST are ≤ 5 times ULN, and ALP is ≤ 6 times ULN; Total ≤ 1.5 × ULN; Albumin ≥ 30 g/L;
  • Renal function: serum creatinine ≤ 1.5 × ULN or rate calculated by Cockroft Gault formula>60 mL/min;
  • Cardiac function: Echocardiography shows a (LVEF) of ≥ 55%; ≤ 480ms; Creatine kinase (CK) ≤ 1 × ULN, troponin/hypersensitive troponin ≤ 1 × ULN;
  • Coagulation function: of prothrombin time (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; 9. Women of childbearing age must undergo a pregnancy test (serum or urine) with a negative result within 14 days before enrollment, and voluntarily use appropriate methods during the observation period and within 3 months after the last administration of the study drug; For males, surgical sterilization or consent to use appropriate contraception methods during the observation period and within 3 months after the last administration of the study drug should be used.

Exclusion criteria

Exclusion Criteria:

  1. Within 4 weeks before the first medication, major surgery (excluding and outpatient minor surgery, such as placement of vascular access) or severe trauma occurred;
  2. There are clinical symptoms of third interstitial fluid accumulation that cannot be controlled by drainage or other methods (such as a large amount of pleural fluid or ascites);
  3. Cardiovascular and cerebrovascular diseases with impaired heart function or significant clinical significance, including but not limited to any of the following:

    Within 6 months prior to the start of treatment, acute coronary syndrome occurred, including acute myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, and stent implantation;

    • Symptomatic congestive heart failure ( classification ≥ II); Evidence of arrhythmia and/or conduction abnormalities within 6 months prior to the start of treatment or at present;
    • Poor control of hypertension (systolic blood pressure ≥ 140 and/or diastolic blood pressure ≥ 90 mmHg under medication control); Abnormal cardiac valve morphology (≥ grade 2) recorded by echocardiography, Note: Patients with grade 1 abnormal valve morphology (such as mild regurgitation/stenosis) are allowed to be enrolled, but patients with moderate valve thickening are prohibited from being enrolled;
    • History of congenital long syndrome; Or those who take drugs known to prolong the QT interval and cannot guarantee discontinuation during the study period;
  4. Previous or screening retinal diseases, such as retinal vein occlusion (RVO), retinal artery occlusion, retinal vasculitis, diabetes retinopathy, hypertensive retinopathy, retinal telangiectasia (Costs disease), retinal pigment epithelial detachment (RPED), etc; Risk factors for RVO during screening (such as uncontrolled glaucoma or high intraocular pressure, history of high viscosity or hypercoagulability syndrome); Retinal diseases such as RPED;
  5. Patients with interstitial lung disease or interstitial pneumonia, including clinically significant radiation pneumonitis (i.e. affecting daily living activities or requiring intervention treatment);
  6. Positive for (HIV) antibodies, syphilis antibodies (Anti TP), virus (HCV) antibodies and HCV RNA, virus surface antigen (HBsAg) and HBV DNA (HBsAg positivity requires further testing for HBV DNA, HBV DNA ≥ 200 IU/ml, or ≥ 103 copies/ml);
  7. History of bone marrow transplantation or organ transplantation;
  8. There are uncontrollable active infectious diseases (such as intravenous drip of antibiotics, antifungal or antiviral drugs) within 2 weeks before the first administration, or fever of unknown cause>38.5 ° C occurs during screening/before the first administration;
  9. Irreversible electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia detected by blood biochemistry);
  10. Neuromuscular diseases related to CK elevation in the past or present (such as inflammatory myopathy, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy, rhabdomyolysis syndrome);
  11. Arterial/venous thrombotic events that occur within 6 months prior to the first use of medication, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;
  12. Within 4 weeks prior to the first use of medication, the occurrence of Grade 3 bleeding symptoms as defined in the National Cancer Institute's (NCI CTCAE v5.0);
  13. Patients with a history of other malignant tumors within the past 5 years, except for those who have been completely cured of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and cervical carcinoma in situ, and/or any malignant tumor patients who have been cured without disease or have had no disease for at least 5 consecutive years;
  14. Individuals who are known to be allergic to any component of the drug;
  15. Have a clear history of neurological or mental disorders, including epilepsy and dementia;
  16. Central nervous system (CNS) ;
  17. Prior to drug administration, all relevant anti-tumor treatment toxicity reactions (excluding hair loss, skin pigmentation, grade 1 chemotherapy related peripheral neurotoxicity, grade 2 toxicity caused by such as elevated blood glucose or hypothyroidism) did not recover to ≤ grade 1 levels (as determined by NCI CTCAE v5.0);
  18. Uncontrolled concomitant diseases, including but not limited to severe diabetes (fasting blood glucose>250 mg/dl or 13.9 mmol/L), or other serious diseases requiring systemic treatment;
  19. Vaccination with live or attenuated vaccine within 4 weeks prior to the first dose (note: if enrolled, subjects must not receive during the study treatment period and within 30 days after the last dose of the study drug);
  20. For premenopausal female subjects ( female patients must have been menopausal for at least 12 months to be considered infertile), the pregnancy test result is positive; During the study period and at least 30 days after the last administration of the study drug, reproductive age subjects (including male subjects' reproductive age female spouses) who are expected to become pregnant, breastfeed, or unwilling to use effective measures;
  21. Patients who are known to be allergic to the components of the investigational drug or its analogues;
  22. Patients who are receiving intravenous or oral medications that affect CYP isoenzymes (strong inducers and inhibitors of CYP2C9 and ) and cannot discontinue the protocol at least one week before starting study treatment and during the study period; I am currently taking drugs with a narrow therapeutic window that are metabolized by CYP1A2;
  23. Inability to swallow capsules or intractable nausea and vomiting, malabsorption, extracorporeal bile diversion, or any significant small bowel resection that may hinder the full absorption of the study drug;
  24. Other situations that researchers consider unsuitable for inclusion. If accompanied by family or social factors, it may affect the safety of the subjects or the collection of data and samples.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Locally advanced or metastatic thyroid cancer with NRAS mutation

    Progressive locally advanced or metastatic radioactive iodine refractory NRAS mutant thyroid cancer

    Drug: Tunlametinib · Drug: Tunlametinib+PD-1 mAb

Interventions

  • Locally advanced or metastatic radioactive iodine refractory NRAS mutant differentiated thyroid cancer

  • DrugTunlametinib+PD-1 mAb

    Locally advanced or metastatic NRAS mutant poor-differentiated, undifferentiated thyroid cancer

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Complete remission rate and partial remission rate

    Time frame: up to approximately 3-5 years

Secondary outcomes

  1. Disease Control Rate

    Complete remission rate and partial remission rate and stable disease rate

    Time frame: up to approximately 3-5 years

  2. Duration of Response

    Time from the date of first partial remission or complete remission to the date of disease progression, or death of any cause, or date of lost follow-up, whichever comes first, otherwise subject data were censored at time last known disease free.

    Time frame: up to approximately 3-5 years

  3. Time to Response

    Time from the initiation of the treatment to the first remission

    Time frame: up to approximately 3-5 years

  4. Progression-free Survival

    Time from the date of enrollment to of disease progression, or death of any cause, or date of lost follow-up, whichever comes first, otherwise subject data were censored at time last known disease free.

    Time frame: up to approximately 3-5 years

  5. Overall Survival

    Time from the date of enrollment to data of death from any cause, or date of lost follow-up, whichever comes first, and otherwise censored at time last known alive.

    Time frame: up to approximately 3-5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 77 non-industry phase 2 interventional studies under Thyroid Neoplasms, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 124. This study's planned 19 months is below that.

Counting every sponsor, half of 92 studies reached it within 73 months; a quarter within 39 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
May 27, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2031
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970353
Lead sponsor
Fudan University
Responsible party
Ji Dongmei (Associated Professor, Fudan University) — Principal investigator
First posted
May 14, 2025
Start date
May 27, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Aug 7, 2025

Study contacts

Dongmei Ji, M.D
Contact
jidongmei2000@hotmail.com
021-64175590 ext. 83650
Yu-Long Wang, M.D
Contact
yulongwang@fudan.edu.cn
021-64175590
Yu-Long Wang, M.D
principal investigator · Fudan University
Qing-Hai Ji, M.D
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tunlametinib

Start the discussion